Training and Resources
LYNPARZA® (olaparib) in prostate cancer
A guide to LYNPARZA® (olaparib) for patients with prostate cancer
GB-47457 | Date of Preparation: August 2023
Prostate prescribing information (tablets) GB / NI
[External links]
Guide for LYNPARZA® (olaparib) BRCA testing in prostate cancer
GB-47458 | Date of Preparation: October 2023
Prostate prescribing information (tablets) GB / NI
[External links]
More information about LYNPARZA® (olaparib) in prostate cancer:
LYNPARZA is indicated as monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.1
LYNPARZA is indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mCRPC in whom chemotherapy is not clinically indicated.1
Reference
- LYNPARZA (tablets) Summary of Product Characteristics.
Supporting documentation
100 mg and 150 mg film coated tablets – Great Britain
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet
100 mg and 150 mg film coated tablets – Northern Ireland
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet
